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Open Forum Infectious Diseases
MAJOR ARTICLE

Changes in Body Mass Index and Atherosclerotic Disease
Risk Score After Switching From Tenofovir Disoproxil
Fumarate to Tenofovir Alafenamide
Jason J. Schafer,1 Kaitlin N. Sassa,1 Jaclyn R. O’Connor,1 Ayako Shimada,2 Scott W. Keith,2 and Joseph A. DeSimone,3

Background. Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-containing antiretroviral
therapy (ART) can improve renal function and bone mineral density in people with human immunodeficiency virus (PWH). The
switch can also negatively influence cholesterol, but changes in body mass index (BMI) and atherosclerotic cardiovascular disease
(ASCVD) risk are unknown.
Methods. This retrospective observational study evaluated BMI and ASCVD risk score changes in virologically suppressed
PWH who switched from TDF to TAF without switching other ART regimen components. Adults on TDF for ≥1 year with 2
consecutive HIV ribonucleic acid values <200 copies/mL before a TAF switch were included. Body weight, BMI, cholesterol,
and ASCVD risk score were collected for the year before and after the switch. Pre- and postswitch values were compared with
the Wilcoxon signed-rank test. Changes in BMI and ASCVD scores were modeled using generalized estimating equations
regression.
Results. One hundred ten patients were included. In unadjusted analyses, there were significant increases in weight, BMI, total
cholesterol, LDL, HDL, and ASCVD risk score in the year after switching from TDF to TAF (each P ≤ .01). In regression models,
switching from TDF to TAF was associated with a 0.45 kg/m2 increase in BMI (95% confidence interval [CI], 0.14–0.76) and a 13%
increase in ASCVD risk score (95% CI, 4%–23%).
Conclusions. We observed significant BMI and ASCVD score increases in PWH 1 year after switching from TDF to TAF. The
mechanism of changes is unclear and requires additional study.
Keywords: BMI; cardiovascular disease risk; HIV; tenofovir alafenamide; weight gain.
Switching from tenofovir disoproxil fumarate (TDF) to
tenofovir alafenamide (TAF)-containing antiretroviral therapy
(ART) can maintain virologic efficacy, while preserving or
improving renal function and bone mineral density in people
with human immunodeficiency virus (PWH) [1–3]. The switch
may also negatively influence cholesterol. Patients that switched
to TAF-containing ART in clinical trials had significant increases in total (Tchol) high-density lipoprotein (HDL-C)
and low-density lipoprotein (LDL-C) cholesterol levels [3–5].
The impact of these changes on atherosclerotic cardiovascular

disease (ASCVD) risk is unclear [6]. In addition, recent studies
suggest that initiating TAF alongside an integrase inhibitor
in treatment-naive patients or switching from TDF to TAF in
treatment-experienced patients can lead to weight gain [7, 8].
Patients in the switch study often had changes in other ART
regimen components, thereby confounding the ability to analyze TAF alone [7]. The purpose of this study was to determine whether changes in weight, body mass index (BMI), and
ASCVD risk score occur after switching from TDF to TAF,
without switching other ART regimen components.
METHODS
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This was a retrospective, observational study involving virally
suppressed PWH who switched from TDF to TAF-containing
ART between January 2016 and March 2018 at an urban, academic medical center. Institutional review board approval
was obtained before data collection. Adult patients on TDFcontaining ART for at least 1 year were included if they had
evidence of persistent viral suppression. This was defined as
having at least 2 consecutive human immunodeficiency virus
(HIV) viral load values <200 copies/mL and no values >200
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Statistical Analysis

Patient demographics were summarized with counts and percentages for categorical variables and summarized with means
and standard deviations or medians and interquartile ranges
(IQRs) for numeric variables. Unadjusted distributions of the
pre- and postswitch values for all study endpoints were summarized with medians and IQRs and compared with Wilcoxon
signed-rank tests. To further investigate the association of
switching from TDF to TAF with BMI and ASCVD risk score,
2 separate generalized estimating equation regression models
were constructed. The covariates selected as candidates for each
model included the following: a pre- versus post-TAF switch indicator, age, sex, race, concomitant medications that can cause
weight gain, concomitant medications that can cause weight
loss, and time since HIV diagnosis. Two-way interactions with
covariates and the pre- versus post-TAF indicator were also assessed. Interaction and main effect terms were removed from
the model one at a time using a hierarchical variable selection
procedure (ie, never removing a main term that is part of an
interaction term in the model) with a final retention criterion
of 0.05. The ASCVD risk scores were highly right-skewed, so
those data were log-transformed before modeling. All the analyses and visualizations were performed and created with SAS
9.4 (SAS Institute Inc., Cary, NC). The significance level of each
test was α = 0.05.
2 • ofid • Schafer et al

RESULTS

A total of 110 patients met study criteria and were included in the
analysis (Table 1). The majority were African American (58.2%)
and male (72.7%) with a mean age of 50 years old. Patients had
been living with HIV and receiving ART for a median of 12 and
8 years, respectively, with persistent viral suppression and immunologic recovery in response to ART. Approximately half of
the patients were receiving integrase inhibitor-based regimens
before their TAF switch.
The majority of subjects (65.5%) were either overweight or
obese at the time they switched to TAF. The median patient
weight was more than 185 pounds with a BMI of 28 kg/m2. In
the year after their switch to TAF, patients had significant unadjusted increases in both weight and BMI. On average, patients
gained 3 pounds and their BMI increased by 0.5 kg/m2 (each
P ≤ .01) (Table 2). In the regression model for BMI, only sex was
retained as a covariate. The results of the model were consistent
with the unadjusted analysis, suggesting that switching from
TDF to TAF was associated with a 0.45 kg/m2 mean increase in
BMI (95% confidence interval [CI], 0.14–0.76).
Unadjusted analyses also showed significant increases in
Tchol, LDL-C, and HDL-C in the year after patients switched
from TDF to TAF (each P ≤ .01) (Table 2). It is notable that,
although the total cholesterol to HDL-C ratio did not change
significantly after the switch, significant changes in ASCVD risk
scores were observed. A total of 91 of 110 patients were between
the ages of 40 and 75 and were eligible for ASCVD score calculations. Of these, 68 had all other data necessary to perform
the calculations both before and after the switch. For these patients, the median ASCVD score rose from 6.9% to 8.1% after
switching to TAF (P < .01). Our regression model, adjusting for
age, sex, race, concomitant medications that can cause weight
gain, and time with HIV, suggested that switching from TDF to
TAF was associated with a 13% average increase in ASCVD risk
score (95% CI, 4%–23%).
DISCUSSION

We observed significant increases in both BMI and ASCVD risk
in PWH who switched from TDF to TAF without changing any
other ART regimen components. Importantly, patients in these
analyses had longstanding HIV infection that was persistently
controlled by ART. Patients were also at or above a normal BMI
when switching to TAF. Therefore, it is unlikely that the weight
gain patients experienced in this study represented a return to
health, which commonly occurs after individuals initiate ART
for the first time [9, 10].
In patients with advanced HIV who are underweight before
starting ART, weight gain can prolong survival [11, 12]. In contrast, being overweight when initiating treatment or becoming
obese on ART can increase a patient’s risk for dyslipidemia, diabetes, hypertension, and cardiovascular disease (CVD) [13–15].
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copies/mL in the year before the TAF switch. Patients were excluded if any other component of their ART regimen changed
in the year before or after the TAF switch.
Demographic data including age, sex, and race were extracted from medical records of eligible patients along with
preswitch CD4 cell counts, concomitant ART agents, duration
of HIV infection, and total years on ART. Any non-ART medications prescribed for chronic use in the year after the TDF to
TAF switch were also collected. Each non-ART medication was
labeled as being associated with weight gain, weight loss, or no
weight change according to package labeling.
To assess the study endpoints, body weight, BMI, Tchol,
LDL-C, HDL-C, and triglyceride values were collected for the
year before and after the switch. Pre- and postswitch median
values for each of these parameters were then calculated.
To determine pre- and postswitch ASCVD risk scores,
the 2018 American College of Cardiology/American Heart
Association guidelines on treating blood cholesterol were used
[6]. According to these guidelines, ASCVD scores can estimate
the 10-year risk of a cardiovascular event in patients between 40
and 75 years old. As a result, only patients between these ages
with all other necessary data points to perform the ACSVD calculation were assessed. Using age, sex, race, cholesterol, blood
pressure, diabetes, and smoking status, ASCVD risk scores were
generated for all eligible patients at the time of the ART switch
and between 6 and 12 months thereafter for comparison.

Table 1.

Demographics and Other Patient Characteristics Summary

Characteristic
Age, mean (SD)

All Patients (n = 110)
50 (11.7)

Sex, n (%)
Male

80 (72.7)

Female

30 (27.3)

Race, n (%)
African American

64 (58.2)

White

38 (34.5)

Hispanic

6 (5.5)

Asian

2 (1.8)

Years since HIV diagnosis, median (IQR)
Preswitch CD4 count (cell/mm3), median (IQR)

8.0 (8.0)
627.5 (381.0)

Preswitch BMI category, n (%)
Underweight

4 (3.6)

Normal weight

34 (30.9)

Overweight

31 (28.2)

Obese

41 (37.3)

Other ART agent, n (%)
Integrase inhibitor

54 (49.1)

Protease inhibitor

18 (16.4)

Nonnucleoside reverse-transcriptase inhibitor

32 (29.1)

Other

6 (5.4)

Concomitant medication cause weight gain, n (%)

34 (30.9)

Concomitant medication cause weight loss, n (%)

29 (26.4)

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.

This is concerning because obesity is becoming increasingly
prevalent in PWH, and these individuals already carry a disproportionate risk for CVD [16–18]. More than half of the patients
in this analysis were overweight or obese at baseline and experienced modest increases in BMI 1 year after switching to TAF.
Importantly even modest increases in BMI may be clinically
relevant. In a recent analysis of over 9000 PWH enrolled in the
Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D)
study, the risk of diabetes and CVD increased by approximately
20% per unit of BMI gained in the year after starting ART
[13]. The extent to which the BMI changes we observed after
Table 2.

Unadjusted Outcomes Summary
Preswitch
(TDF)

Postswitch (TAF)

Weight (lbs), median (IQR)

185.4 (55.8)

190.5 (60.5)

3.0 (9.2)

<.01

BMI (kg/m2), median (IQR)

28.0 (10.8)

28.2 (10.0)

0.5 (1.4)

<.01

Total cholesterol, median (IQR)

173.8 (44.0)

195.0 (42.0)

12.5 (32.3)

<.01

LDL cholesterol, median (IQR)

98.6 (40.2)

112.1 (46.6)

8.2 (21.0)

<.01

HDL cholesterol, median (IQR)

51.0 (19.0)

55.8 (24.0)

3.0 (12.0)

<.01

3.5 (1.6)

3.5 (1.7)

0.1 (0.6)

103.5 (68.0)

109.5 (93.0)

4.0 (64.0)

Outcome Variable

Total to HDL cholesterol ratio, median (IQR)
Triglyceride levels, median (IQR)
Atherosclerotic CVD risk score, median (IQR)
Creatinine clearance, median (IQR)

6.9 (8.1)
104.0 (38.0)

8.1 (10.9)
102.5 (42.0)

Change (Post–Pre)

0.4 (1.9)
−1.0 (17.0)

P Value

.25
.28
<.01
.82

Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; TAF, tenofovir alafenamide; TDF,
tenofovir disoproxil fumarate.
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Years on ART, median (IQR)

12.0 (11.0)

switching ART could influence a patient’s risk of developing diabetes or CVD is unclear.
In terms of dyslipidemia, we observed significant increases
in Tchol, LDL-C, and HDL-C in our patients after switching
to TAF. These findings are consistent with observations from
clinical trials. Also consistent with previous trials, we did not
observe changes in Tchol/HDL-C ratios. Current guidelines on
treating blood cholesterol recommend calculating an ASCVD
risk score using cholesterol data in addition to a person’s age,
sex, race, blood pressure, and smoking status [6]. When performing this assessment for our patients, we observed a 13%
increase in ASCVD risk scores after switching to TAF. This resulted in many patients becoming eligible for treatment with a
statin medication for ASCVD risk reduction. More specifically,
before TAF, the median ASCVD risk score in our sample was
6.9%, indicating that over half (53.3%) of the sample was below
the threshold of 7.5% to meet statin eligibility criterion. After
switching to TAF, the average 13% increase in ASCVD risk
scores shifted 50.7% of our sample over the 7.5% statin criterion. Taken together with the increases in BMI and cholesterol,
the changes in ASCVD risk score may indicate an increased risk
for CVD in PWH after switching from TDF to TAF.
This study has several limitations. First, as an observational
study, the results cannot establish causal relationships between
TAF and increases in BMI or ASCVD risk. Second, as a retrospective chart review, we relied on the accuracy and completeness of medical records, but omissions or inaccuracies that
influenced the results were possible. In addition, although we
made every attempt to control for confounding variables with
restrictive inclusion criteria and statistical analyses, it remains
possible that data not measured or collected could have influenced our results. For example, we were unable to collect data
on patients’ caloric intake and physical activity. Finally, our cohort was predominantly African American and male from a
single academic center in the Northeastern United States. As
a result, the findings may not be generalizable to other populations. Given these limitations, additional investigations will be
necessary to determine whether there are causal relationships

between TAF exposure and increases in BMI or ASCVD risk. If
relationships do exist, the associated mechanisms and any additional risk factors should be determined to optimize treatment
for all PWH.
CONCLUSIONS

We observed significant increases in BMI and ASCVD risk in
PWH 1 year after a switch from TDF to TAF without changes in
other ART regimen components. The mechanisms associated with
these metabolic changes are unclear and require additional study.
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